NEW TREATMENTS FOR PATIENTS WITH MENTAL ILLNESS
Associate Professor Bernadette Fitzgibbon
Director of Psychiatry Research
Paratus Clinical, Australia &
Associate Professor,
Australian National University, Canberra, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | November 2025
Associate Professor Bernadette Fitzgibbon is a neuroscientist with several decades of experience in researching, developing, and translating novel therapies for mental health and chronic pain conditions. This includes the application and optimisation of brain stimulation and psychedelic therapies, overseeing large multi-site intervention trials, both within Australia and abroad. Through her work, she has developed meaningful collaborations with consumers, volunteers, policy makers, and services providers, ensuring that the outcomes of her work contribute towards real-world clinical impact.
She is currently the Director of Psychiatry Research at Paratus Clinical, where she leads the delivery of clinical trials in emerging therapies for psychiatry, collaborating with academic institutions, pharmaceutical and biotechnology companies. She is also an Associate Professor at the Australian National University, where she contributes to novel investigator-initiated trials within interventional psychiatry and clinical neuroscience, and a consultant at The Psychedelic Consultancy: a hub to connect and support professionals navigate the legal psychedelic assisted psychotherapy ecosystem in Australia and internationally. Together, she is dedicated to changing the landscape of mental health treatments to improve the outcomes for people living with mental illness.
Source: Supplied
You Might also like
-
Public health and research into Ear, Nose and Throat conditions
Associate Professor Paul Paddle is an Ear, Nose and Throat (ENT) surgeon, head and neck surgeon with fellowship training in Laryngology – Voice, airway and Swallowing disorders. Working at Monash Health and Monash Children’s hospital, Paul has extensive experience managing a wide range of paediatric ENT conditions, from neonates to adolescents. He is also an active researcher in paediatric obstructive sleep apnoea and sleep disorders.
-
Applying nanotechnology to chronic pain management
Dr Felicity Han is a Research Fellow and Leader in Pain Relief Innovation, at the Australian Institute for Bioengineering and Nanotechnology in the University of Queensland. Dr Han’s research interests sit at the interface of drug delivery and the pain field. Her overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management.
-
Nanoparticles & microparticles to combat antimicrobial resistance
Dr Anjana Jayasree is an emerging research leader in biomaterials, tissue engineering and nanotechnology, recognised internationally for her innovative work on antimicrobial nanoparticles and regenerative therapies. A Postdoctoral Research Fellow at The University of Queensland, she operates at the intersection of materials science, drug delivery and cellular biology, developing advanced metallic-based nanotechnologies to improve both human and animal health outcomes. Her expertise spans nanoparticle synthesis, cell–material interactions, and the design of sophisticated in vitro models to investigate soft-tissue integration, osseointegration, angiogenesis and biofilm formation.
https://orcid.org/0000-0002-5339-5304